IOTECH: Present, future and the future of the future

por Haanen, John B.
Publicado 2019

The promise of IO and IOTECH

por Haanen, John B.
Publicado 2019

Getting visible with exciting IO tech!

por Haanen, John B.
Publicado 2019

Immunotherapy of melanoma

por Haanen, John B.A.G.
Publicado 2013

Questions asked in the everyday practice: immune checkpoint inhibitors

por Haanen, John B A G
Publicado 2018

TIL classified to memory state are correlated with response to immune checkpoint blockade

por Jedema, Inge, Haanen, John B.
Publicado 2022

Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers

por Tas, Liselotte, Jedema, Inge, Haanen, John B.A.G.
Publicado 2023

Adoptive cellular therapies: the current landscape

por Rohaan, Maartje W., Wilgenhof, Sofie, Haanen, John B. A. G.
Publicado 2018

Clinical advances and ongoing trials of mRNA vaccines for cancer treatment

por Lorentzen, Cathrine Lund, Haanen, John B, Met, Özcan, Svane, Inge Marie
Publicado 2022

Naked Plasmid DNA Formulation: Effect of Different Disaccharides on Stability after Lyophilisation

por Quaak, Susanne G. L., Haanen, John B. A. G., Beijnen, Jos H., Nuijen, Bastiaan
Publicado 2010

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events

por Hoefsmit, Esmée P., Rozeman, Elisa A., Haanen, John B. A. G., Blank, Christian U.
Publicado 2019

Selective Expansion of Cross-Reactive Cd8(+) Memory T Cells by Viral Variants

por Haanen, John B.A.G., Wolkers, Monika C., Kruisbeek, Ada M., Schumacher, Ton N.M.
Publicado 1999

Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma

por Wolf, Sanne EJ, Meenken, Christina, Moll, Annette C, Haanen, John B, van der Heijden, Michiel S
Publicado 2013

Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option

por Rohaan, Maartje W., van den Berg, Joost H., Kvistborg, Pia, Haanen, John B. A. G.
Publicado 2018

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product

por Lindenberg, Melanie A., Retèl, Valesca P., van den Berg, Joost H., Geukes Foppen, Marnix H., Haanen, John B., van Harten, Wim H.
Publicado 2018

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

por Fendler, Annika, de Vries, Elisabeth G. E., GeurtsvanKessel, Corine H., Haanen, John B., Wörmann, Bernhard, Turajlic, Samra, von Lilienfeld-Toal, Marie
Publicado 2022

Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy

por Borm, Frank J., Smit, Jasper, Oprea-Lager, Daniela E., Wondergem, Maurits, Haanen, John B. A. G., Smit, Egbert F., de Langen, Adrianus J.
Publicado 2021

Fixed Dosing of Monoclonal Antibodies in Oncology

por Hendrikx, Jeroen J.M.A., Haanen, John B.A.G., Voest, Emile E., Schellens, Jan H.M., Huitema, Alwin D.R., Beijnen, Jos H.
Publicado 2017

Transgenerational transfer of gene-modified T cells

por Cosgrove, Cormac, Dellacecca, Emilia R., van den Berg, Joost H., Haanen, John B., Nishimura, Michael I., Le Poole, I. Caroline, Bergmans, Hans E. N.
Publicado 2019

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation

por Retèl, Valesca P., Steuten, Lotte M. G., Geukes Foppen, Marnix H., Mewes, Janne C., Lindenberg, Melanie A., Haanen, John B. A. G., van Harten, Wim H.
Publicado 2018